Specialists from the Federal Medical-Biological Agency (FMBA) are developing two new gene therapy vaccines for the treatment of HIV infection: "CombiMab-1" and "CombiMab-2".
"CombiMab-1" has already passed preclinical studies and demonstrated its safety, providing protection for at least one and a half years. It helps against a wide range of HIV variants after a single administration. The preparation for clinical trials is currently underway.
The vaccines contain a combination of three broadly neutralizing antibodies that are delivered using an adeno-associated vector. "CombiMab-1" has the potential to significantly improve HIV therapy by eliminating the need for daily medication, which simplifies treatment and reduces side effects. The drug can also be used for HIV prevention.
The second vaccine, "CombiMab-2", is also based on an adeno-associated vector and expresses broadly neutralizing antibodies to HIV. Preclinical studies of this vaccine are scheduled to be completed in the first quarter of 2026. Its clinical trials will begin in 2027.
Both vaccines represent a new class of drugs aimed at reducing the viral load of HIV and potentially changing the approach to the treatment and prevention of this infection.
Read materials on the topic:
A modern pharmaceutical production facility has appeared in "Technopolis Moscow"
